Literature DB >> 21402977

Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts.

Ashish Thakur1, Rajendra Kadam, Uday B Kompella.   

Abstract

OBJECTIVE: To determine whether adverse effects such as elevated intraocular pressure and cataracts, which are lower with dexamethasone when compared with fluocinolone acetonide or triamcinolone acetonide, may be explained in part by the differences in drug lipophilicity and partitioning of these drugs into the trabecular meshwork and lens.
METHODS: The n-octanol/phosphate-buffered saline (pH 7.4) partition coefficient (log distribution coefficient [D]) and bovine/human ocular tissue partition coefficients were determined for triamcinolone, prednisolone, dexamethasone, fluocinolone acetonide, triamcinolone acetonide, and budesonide at 37°C.
RESULTS: The log D of the corticosteroids ranged from 0.712 to 2.970. The ranges of tissue:PBS partition coefficients following drug incubation at 0.4, 2.0, and 10.0 μg/mL were 0.35 to 1.56, 0.30 to 2.12, and 0.30 to 1.95, respectively, for the bovine lens, 0.87 to 4.18, 0.71 to 4.40, and 0.69 to 5.86, respectively, for the human lens, and 2.98 to 9.48, 2.41 to 9.16, and 1.71 to 9.96, respectively, for the bovine trabecular meshwork. In general, tissue partitioning showed a positive correlation with log D. Dexamethasone, with lipophilicity less than triamcinolone acetonide and fluocinolone acetonide, exhibited the least amount of partitioning in the trabecular meshwork and lens among these 3 corticosteroids commonly used for treating diseases at the back of the eye.
CONCLUSION: Binding of corticosteroids to the trabecular meshwork and lens increases as drug lipophilicity increases. CLINICAL RELEVANCE: Less lipophilic corticosteroids with limited partitioning to the trabecular meshwork and lens may result in reduced incidence of elevated intraocular pressure and cataracts.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21402977      PMCID: PMC3407594          DOI: 10.1001/archophthalmol.2011.39

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  14 in total

1.  A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results.

Authors:  Mark C Gillies; Judy M Simpson; Wei Luo; Philip Penfold; Alex B L Hunyor; William Chua; Paul Mitchell; Frank Billson
Journal:  Arch Ophthalmol       Date:  2003-05

Review 2.  Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature.

Authors:  Relief Jones; Douglas J Rhee
Journal:  Curr Opin Ophthalmol       Date:  2006-04       Impact factor: 3.761

3.  Aqueous solubility, n-octanol-water partition coefficient, and sorption of five selective serotonin reuptake inhibitors to sediments and soils.

Authors:  Jeong-Wook Kwon; Kevin L Armbrust
Journal:  Bull Environ Contam Toxicol       Date:  2008-04-04       Impact factor: 2.151

4.  Similarity of the yellow chromophores isolated from human cataracts with those from ascorbic acid-modified calf lens proteins: evidence for ascorbic acid glycation during cataract formation.

Authors:  R Cheng; B Lin; K W Lee; B J Ortwerth
Journal:  Biochim Biophys Acta       Date:  2001-07-27

5.  Cataract progression after intravitreal triamcinolone injection.

Authors:  Osman Cekiç; Stanley Chang; Joseph J Tseng; Yusuf Akar; Gaetano R Barile; William M Schiff
Journal:  Am J Ophthalmol       Date:  2005-06       Impact factor: 5.258

6.  Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study.

Authors:  Glenn J Jaffe; Daniel Martin; David Callanan; P Andrew Pearson; Brian Levy; Timothy Comstock
Journal:  Ophthalmology       Date:  2006-05-09       Impact factor: 12.079

Review 7.  Differentiating intraocular glucocorticoids.

Authors:  Jeffrey L Edelman
Journal:  Ophthalmologica       Date:  2010-08-18       Impact factor: 3.250

8.  Steroid-induced ocular hypertension in normal sheep.

Authors:  Rosana Gerometta; Steven M Podos; John Danias; Oscar A Candia
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-09-29       Impact factor: 4.799

Review 9.  The etiology of steroid cataract.

Authors:  Eric R James
Journal:  J Ocul Pharmacol Ther       Date:  2007-10       Impact factor: 2.671

10.  Clinical detection of precataractous lens protein changes using dynamic light scattering.

Authors:  Manuel B Datiles; Rafat R Ansari; Kwang I Suh; Susan Vitale; George F Reed; J Samuel Zigler; Frederick L Ferris
Journal:  Arch Ophthalmol       Date:  2008-12
View more
  26 in total

1.  Expression of concern: Thakur A, Kadam R, Kompella UB. Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts. Arch Ophthalmol. 2011:129(7):914-920.

Authors:  Neil M Bressler; Howard Bauchner
Journal:  JAMA Ophthalmol       Date:  2015-04       Impact factor: 7.389

2.  Influence of drug solubility and lipophilicity on transscleral retinal delivery of six corticosteroids.

Authors:  Ashish Thakur; Rajendra S Kadam; Uday B Kompella
Journal:  Drug Metab Dispos       Date:  2011-02-23       Impact factor: 3.922

3.  OCULAR HYPERTENSION AFTER INTRAVITREAL DEXAMETHASONE (OZURDEX) SUSTAINED-RELEASE IMPLANT.

Authors:  Eric K Chin; David R P Almeida; Gabriel Velez; Kunyong Xu; Maria Peraire; Maria Corbella; Yasser M Elshatory; Young H Kwon; Karen M Gehrs; H Culver Boldt; Elliott H Sohn; Stephen R Russell; James C Folk; Vinit B Mahajan
Journal:  Retina       Date:  2017-07       Impact factor: 4.256

4.  Intravitreal injection versus systematic treatment in patients with uveitis undergoing cataract surgery: a systematic review and meta-analysis.

Authors:  Yun-Hsiu Hsieh; Hong-Jie Jhou; Po-Huang Chen; Yih-Shiou Hwang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-10-22       Impact factor: 3.535

5.  Dexamethasone implant in diabetic macular edema in real-life situations.

Authors:  J Chhablani; P Bansal; D Veritti; S Sambhana; V Sarao; F Pichi; P Carrai; D Massaro; A Lembo; A M Mansour; A Banker; S R Gupta; R Hamam; P Lanzetta
Journal:  Eye (Lond)       Date:  2015-11-27       Impact factor: 3.775

Review 6.  Model systems for the study of steroid-induced IOP elevation.

Authors:  Ilya Rybkin; Rosana Gerometta; Gabrielle Fridman; Oscar Candia; John Danias
Journal:  Exp Eye Res       Date:  2016-07-20       Impact factor: 3.467

Review 7.  Perspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema.

Authors:  Hemal Mehta; Mark Gillies; Samantha Fraser-Bell
Journal:  Ther Adv Chronic Dis       Date:  2015-09       Impact factor: 5.091

8.  Long-term efficacy and duration of action of dexamethasone implant, in vitrectomised and non-vitrectomised eyes with persistent diabetic macular oedema.

Authors:  George G Bastakis; Dimitris Dimopoulos; Anastasios Stavrakakis; George Pappas
Journal:  Eye (Lond)       Date:  2018-10-09       Impact factor: 3.775

Review 9.  Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives.

Authors:  Sherif A Gaballa; Uday B Kompella; Omar Elgarhy; Ali M Alqahtani; Barbara Pierscionek; Raid G Alany; Hamdy Abdelkader
Journal:  Drug Deliv Transl Res       Date:  2021-06       Impact factor: 4.617

10.  Dexamethasone intravitreal implant for the treatment of noninfectious uveitis.

Authors:  Rebecca S Hunter; Ann-Marie Lobo
Journal:  Clin Ophthalmol       Date:  2011-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.